Rapid-infusion rituximab in lymphoma treatment [3]

Annals of Oncology

Volumn 17, Issue 6, 2006, Pages 1027-1028

  Provencio, M ^a   Cerdeira, S ^a   Bonilla, F ^a   Sanchez A ^a   Espana P ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ANGIONEUROTIC EDEMA; B CELL LYMPHOMA; BRONCHOSPASM; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CHILL; DRUG BINDING; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DYSPNEA; FEVER; FOLLICULAR LYMPHOMA; HODGKIN DISEASE; HUMAN; HYPERKALEMIA; HYPERURICEMIA; HYPOCALCEMIA; INFUSION RATE; LETTER; MANTLE CELL LYMPHOMA; MAXIMUM PERMISSIBLE DOSE; MONOTHERAPY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RESPIRATORY FAILURE; SKIN MANIFESTATION; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME; URTICARIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; TIME FACTORS;

EID: 33646878576     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj103     Document Type: Letter

References (6)

1. Feugier P, Van Hoof A, Sebban C et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the groupe d'Etude des lymphomes de l'Adulte. J Clin Oncol 2005; 23: 4117-4126.
2. Marcus R, Imrie K, Belch A et al. CVP chemotherapy plus rituximab compared with CVP as first line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417-1423.
3. Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of antiCD20 reagents. Blood 2004; 103: 2738-2743.
4. Smith MR. Rituximab (monoclonal antiCD20 antibody): Mechanisms of action and resistance. Oncogene 2003; 22: 7359-7368.
5. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
6. Sehn L, Donaldson J, Filewich A et al. Rapid infusion Rituximab can be safely administered and has a positive impact on resource utilization. Ann Oncol 2005; 16 (Suppl 5): V69 (Abstr 107).